Ernie Tremblay- Money Morning - Only the News You Can Profit From.
Once singled out as the "most winning" stock-picker in the investment newsletter industry, Ernie Tremblay has more than 25 years of experience in following and analyzing the latest developments in health, medicine, and related technologies.
As a health editor and writer, he has contributed to more than 100 publications on topics like diabetes, Alzheimer's disease, arthritis, dermatology, and groundbreaking medical therapies, for top publishers such as Prentice Hall, Harper Collins, and others. Over the decades, Ernie has gained "insider" access to some of the world's top medical professionals, including Nobel-caliber doctors like Yale's Karel Liem, Columbia's George Gaylord Simpson, and Harvard's William S. Beck.
Ernie understands the FDA approval process, as well as the "hard science" behind new, experimental drugs and the market demand for them - and has a comprehensive grasp of the complex dynamics that determine whether a new drug will be a breakthrough winner, or just another casualty of the FDA approval process.
He puts that knowledge to work for members of his Biotech Insider Alert service, using a proprietary Three-Phase System that identifies the next "blockbuster" drugs and determines whether upcoming regulatory events will make a stock rocket skyward or plunge in the opposite direction . As a consulting editor for Money Map Press since 2012, Ernie's service has given readers opportunities to land substantial gains - including one bioscience stock that generated triple-digit gains four times in eight months.
Ernie'S LATEST HEADLINES
Biotechs 0 Thursday, March 16, 2017This "Quick Doubler" Biotech Will Likely Disappoint
Stroke kills an American every four minutes – more than 525,000 individuals each year – and nearly 300,000 more fall victim to its debilitating consequences.
The onset of symptoms signal a dire emergency. According to the National Stroke Association, they can include:
- Sudden numbness or weakness of the face, arm or leg, especially on one side of the body;
- Sudden confusion, trouble speaking or understanding;
- Sudden trouble seeing or blurred vision in one or both eyes; and/or
- Sudden trouble walking, dizziness, loss of balance or coordination.
There are two types of stroke: hemorrhagic and ischemic. The first results from a ruptured blood vessel in the brain, and the other from an inadequate blood supply, usually due to a blood clot blocking an artery that feeds the brain.
The second variety, ischemic stroke, is by far the more common. Nearly nine out of 10 are of this type. And that's fortunate, because an ischemic stroke could be relatively easy to prevent – provided you see it coming.
If you had the technology to find and map arterial blockages safely, simply, and quickly, you could intervene with a relatively simple medical procedure, clear the blockage, and bring down that enormous annual incidence of stroke to a much smaller number.
Does such a technology exist?
Currently, doctors can use an ultrasound machine to detect the presence of an occlusion (blockage) or stenosis (narrowing) in a carotid or cerebral artery, but the patient then has to undergo a CT scan or MRI for more definitive information.
It's a complicated, drawn-out, and extremely expensive process, and you would think a single-step, cheaper technology might be a game changer – and represent a windfall for investors.
One micro-cap biotech in Vancouver, Canada, CVR Medical, is counting on exactly that with its new carotid stenotic scan (CSS) device.
The device is about to enter pivotal clinical trials, and after they're completed, will go to the U.S. Food and Drug Administration (FDA) for marketing approval.
The CSS could save the government up to $34 billion a year, according to the CDC, and more importantly, hundreds of thousands of lives in the United States and around the world.
That's great news for patients and their families. And it has proven a terrific opportunity for investors, too. Since the company's IPO in November 2016, the stock is already up over 90%.
But here's the thing. This device may not be the silver bullet it's cracked up to be. And the stock isn't, either.I'm going to show you what's really happening here and how to ultimately profit on this situation. It's a great example of how independent research can save you a lot of money in the long run...
Best Profit Opportunities 0 Thursday, March 31, 2016How to Protect Your Biotech Profits from This Legal Limbo
Biotechs 3 Monday, February 1, 2016How to Make a (Consistent) Killing in Biotech Investing in 2016
Biotechs 0 Friday, September 25, 2015What Hillary's Pharma Plan Means for Biotech Investors
Biotechs 9 Thursday, August 20, 2015Two Tactics for Bigger Biotech Investing Profits
Biotechs 7 Friday, August 7, 2015This Bioscience Company Has "Nearly Limitless" Income Potential
Biotechs 2 Friday, June 19, 2015These Promising Cancer Therapies Are a Biotech "Triple Play"
Biotechs 3 Tuesday, May 26, 2015"21st Century Cures" Could Revolutionize Biotech
Biotechs 3 Friday, April 3, 2015How to Profit from America's $20 Billion Waistline War
Biotechs 3 Friday, February 20, 2015How to Find the Best Biotech Shares – Every Time